Literature DB >> 2903623

Plasma concentrations of sulfadoxine in healthy and malaria infected Thai subjects.

B Sarikabhuti1, N Keschamrus, S Noeypatimanond, E Weidekamm, R Leimer, W Wernsdorfer, E U Kölle.   

Abstract

The disposition of sulfadoxine was studied in the presence of pyrimethamine in 18 healthy Thai subjects who had been suffering from falciparum malaria in the 6 months prior to the study, and in 12 Thai patients with acute malaria. The volunteers were administered an oral dose of 500 mg sulfadoxine + 25 mg pyrimethamine (1 Fansidar tablet). They were classified retrospectively as responders (Group I, n = 8) or nonresponders (Group II, n = 10) according to previous response to treatment with Fansidar. The patients were treated with 3 Fansidar tablets corresponding to 1500 mg sulfadoxine and 75 mg pyrimethamine. Five of them were completely cured. Seven patients showed R I or R II resistance. In all cases blood samples were collected up to 288 h post dose. The resultant plasma was analyzed for active (i.e. unchanged) and total sulfadoxine using a modified Bratton-Marshall method. In the healthy volunteers the plasma concentration time course of total sulfadoxine was similar for responding and nonresponding subjects. However, in nonresponders active sulfadoxine tended to show shorter half-lives (harmonic means were 212 h vs 267 h, respectively). Furthermore, significantly higher amounts of metabolites (mainly N4-acetylsulfadoxine) were present in plasma of nonresponders. In contrast to these findings, in malaria patients, plasma concentrations of active and total sulfadoxine were even higher in nonresponders as compared to the subjects who could be successfully cured. Furthermore, in this case there was no increase of the amount of metabolites in plasma.(ABSTRACT TRUNCATED AT 250 WORDS)

Entities:  

Mesh:

Substances:

Year:  1988        PMID: 2903623

Source DB:  PubMed          Journal:  Acta Trop        ISSN: 0001-706X            Impact factor:   3.112


  5 in total

1.  Pharmacokinetic properties of sulfadoxine-pyrimethamine in pregnant women.

Authors:  Harin A Karunajeewa; Sam Salman; Ivo Mueller; Francisca Baiwog; Servina Gomorrai; Irwin Law; Madhu Page-Sharp; Stephen Rogerson; Peter Siba; Kenneth F Ilett; Timothy M E Davis
Journal:  Antimicrob Agents Chemother       Date:  2009-07-20       Impact factor: 5.191

2.  Competitive facilitation of drug-resistant Plasmodium falciparum malaria parasites in pregnant women who receive preventive treatment.

Authors:  W E Harrington; T K Mutabingwa; A Muehlenbachs; B Sorensen; M C Bolla; M Fried; P E Duffy
Journal:  Proc Natl Acad Sci U S A       Date:  2009-05-18       Impact factor: 11.205

3.  How frequent are notified severe cutaneous adverse reactions to Fansidar?

Authors:  D Stürchler; M L Mittelholzer; L Kerr
Journal:  Drug Saf       Date:  1993-02       Impact factor: 5.606

4.  Population Pharmacokinetic Properties of Sulfadoxine and Pyrimethamine: a Pooled Analysis To Inform Optimal Dosing in African Children with Uncomplicated Malaria.

Authors:  Miné de Kock; Joel Tarning; Lesley Workman; Elizabeth N Allen; Mamadou M Tekete; Abdoulaye A Djimde; David J Bell; Steve A Ward; Karen I Barnes; Paolo Denti
Journal:  Antimicrob Agents Chemother       Date:  2018-04-26       Impact factor: 5.191

5.  Trimester-Specific Population Pharmacokinetics and Other Correlates of Variability in Sulphadoxine-Pyrimethamine Disposition Among Ugandan Pregnant Women.

Authors:  Charles O Odongo; Kuteesa R Bisaso; Muhammad Ntale; Gordon Odia; Francis W Ojara; Josaphat Byamugisha; Jackson K Mukonzo; Celestino Obua
Journal:  Drugs R D       Date:  2015-12
  5 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.